SCHEMBL20028835

SCHEMBL20028835

CCNCCN1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5430626 0.95 PRMT6 (0.58)
SCHEMBL2003710 0.93 PRMT6 (0.56)
SCHEMBL13178507 0.93 PRMT6 (0.56)
SCHEMBL4783223 0.90 ACE2 (0.54)
SCHEMBL13660816 0.89 PRMT6 (0.43)
SCHEMBL19071988 0.85 ACE2 (0.56)
SCHEMBL7730804 0.83 ACE2 (0.48)
SCHEMBL10282545 0.83 ACE2 (0.48)
SCHEMBL24971199 0.82 CXCR4 (0.58)
SCHEMBL6733235 0.81 CARM1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851073-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof ABBVIE INC. (US) 2020-12-01 US disclosed
WO-2018064557-A1 SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS Epizyme, Inc. (US) 2018-04-05 WO disclosed